The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...

In 2023, the first CRISPR–(Cas9)-based product was approved by the US Food and Drug Administration (FDA): Vertex/CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel) for sickle cell disease (SCD) ...

Imagination pairs with plant breeding innovation using tools such as gene editing and cyber agriculture to redefine ...

Gene editing tools are powering new innovation in the plant sciences world, but that brings new considerations of intellectual property and regulatory risks. Ever since powerful new gene editing tools ...

The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling ...

Bread and biscuits made from Crispr-edited wheat showed substantially reduced acrylamide levels, even after toasting ...

June 17 (UPI) --Eli Lilly and Company said Tuesday it will buy out Boston-based Verve Therapeutics Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health ...

Gene editing techniques, including CRISPR, prime editing, and nucleases, allow scientists to tackle genetic diseases, cancer, and more. Researchers increasingly apply these techniques to study and ...

Scientists are working to improve gene editing technologies to make them better suited for clinical translation, including seeking solutions for better gene editor delivery, precision, efficiency, and ...

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement, the pharmaceutical company ...

Shares of Verve Therapeutics soared 75% in premarket trading Tuesday as Eli Lilly said it would acquire the gene-editing startup. The deal values Verve at about $1.3 billion, with some of Eli Lilly's ...